- 全部删除
- 您的购物车当前为空

MK-0429 is an orally active, selective, and nonpeptide antagonist of αvβ3 integrin (IC50: 80 nM).
MK-0429 is an orally active, selective, and nonpeptide antagonist of αvβ3 integrin (IC50: 80 nM).
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
5 mg | ¥ 3,730 | 5日内发货 | |
10 mg | ¥ 6,230 | 5日内发货 | |
1 mL x 10 mM (in DMSO) | ¥ 4,120 | 5日内发货 |
产品描述 | MK-0429 is an orally active, selective, and nonpeptide antagonist of αvβ3 integrin (IC50: 80 nM). |
靶点活性 | α5β1:12.2 nM (fibronectin-binding), αvβ5:0.1 nM (vitronectin-binding), αvβ1:1.6 nM (fibronectin-binding), αvβ6:0.7 nM (LAP-binding), αvβ8:0.5 nM (LAP-binding), αvβ3 integrin:80 nM |
体内活性 | MK-0429 is safe and efficacious in obviously reducing melanoma metastasis in the lungs. MK-0429 (100 or 300 mg/kg, p.o., twice daily b.i.d., 2 weeks) decreases metastatic tumor colony formation and area in the lungs [1]. |
别名 | L-000845704 |
分子量 | 439.51 |
分子式 | C23H29N5O4 |
CAS No. | 227963-15-7 |
密度 | 1.36 g/cm3 (Predicted) |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 250 mg/mL (568.82 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
|
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
评论内容